These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8938825)

  • 21. Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
    Sato S; Someya T; Shioiri O; Koitabashi T; Inoue Y
    Pharmacol Toxicol; 2000 Mar; 86(3):145-8. PubMed ID: 10752674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
    Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
    Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Otani K; Furukori H; Kaneko S; Inoue Y
    Eur Arch Psychiatry Clin Neurosci; 2001; 251(2):57-9. PubMed ID: 11407439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.
    Yasui-Furukori N; Saito M; Furukori H; Inoue Y; Someya T; Kaneko S; Tateishi T
    Ther Drug Monit; 2004 Jun; 26(3):336-41. PubMed ID: 15167638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The characteristics of side-effects of bromperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Ishida M; Tanaka O; Mihara K; Kaneko S; Otani K
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):103-6. PubMed ID: 11929578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
    Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
    J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients.
    Sommers DK; Snyman JR; van Wyk M; Blom MW; Huang ML; Levron JC
    Int Clin Psychopharmacol; 1997 May; 12(3):141-5. PubMed ID: 9248870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
    Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
    J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
    J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
    Spina E; Gitto C; Avenoso A; Campo GM; Caputi AP; Perucca E
    Eur J Clin Pharmacol; 1997; 51(5):395-8. PubMed ID: 9049581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
    Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
    Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.
    Dencker SJ; Giös I; Mårtensson E; Nordén T; Nyberg G; Persson R; Roman G; Stockman O; Svärd KO
    Psychopharmacology (Berl); 1994 Feb; 114(1):24-30. PubMed ID: 7846204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
    Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
    Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
    Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
    J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.